Discontinuation/interruption of warfarin therapy in patients with nonvalvular atrial fibrillation

Journal of Managed Care Pharmacy

Volumn 21, Issue 7, 2015, Pages 596-606

  Spivey, Christina A ^a   Qiao, Yanru ^a   Liu, Xianchen ^a,b   Mardekian, Jack ^b   Parker, Robert B ^a   Phatak, Hemant ^c   Claflin, Abigail B ^b   Kachroo, Sumesh ^c   Abdulsattar, Younos ^b   Chakrabarti, Anwesa ^a   Wang, Junling ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^b PFIZER INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

AGED; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CHADS2 SCORE; CHARLSON COMORBIDITY INDEX; CLINICAL PRACTICE; COHORT ANALYSIS; DEMOGRAPHY; DRUG WITHDRAWAL; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HEALTH STATUS; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NONVALVULAR ATRIAL FIBRILLATION; PATIENT MONITORING; PREFERRED PROVIDER ORGANIZATION; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT WITHDRAWAL; UNITED STATES; AGE; COMPLICATION; FACTUAL DATABASE; MEDICATION COMPLIANCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; UNITED STATES; WARFARIN;

EID: 84934762423     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.7.596     Document Type: Article

References (37)

1. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol.2006;48(4):854-906.
2. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol.2011;57(2):223-42.
3. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J.2010;31(19):2369-429.
4. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285(18):2370-75.
5. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol.2013;112(8):1142-47.
6. National Institutes of Health. What is atrial fibrillation? September 18, 2014. Available at: http://www.nhlbi.nih.gov/health/health-topics/topics/af/. Accessed May 15, 2015.
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-88.
8. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S-e75S.
9. Rietbrock S, Plumb JM, Gallagher AM, van Staa TP. How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. Thromb Haemost.2009;101(3):527-34.
10. Fang MC, Go AS, Chang Y, et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012;43(7):1795-99.
11. Darkow T, Vanderplas AM, Lew KH, Kim J, Hauch O. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin.2005;21(10):1583-94.
12. Ghate SR, Biskupiak J, Ye X, Kwong WJ, Brixner DI. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm.2011;17(9):672-84. Available at: http:// www.amcp.org/JMCP/2011/November-_December/13680/1033.html.
13. Peterson P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1(8631):175-79.
14. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med. 1990;322(12):863-68.
15. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. New Engl J Med.1990;323(22):1505-11.
16. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. New Engl J Med.1992;327(20):1406-12.
17. Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in Medicare beneficiaries with nonvalvular atrial fibrillation. Stroke. 2011;42(1):112-18.
18. Suh DC, Choi JC, Schein J, Kim S, Nelson WW. Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients. Curr Med Res Opin.2013;29(7):761-71.
19. Kim MM, Metlay J, Cohen A, et al. Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults. Pharmacoepidemiol Drug Saf.2010;19(7):731-36.
20. Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes.2010;3(6):624-31.
21. Ewen E, Zhang Z, Simon TA, Kolm P, Liu X, Weintraub WS. Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices. Vasc Health Risk Manag.2012;8:587-98.
22. Reynolds MR, Shah J, Essebag V, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol.2006;97(4):538-43.
23. Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis. J Thromb Haemost.2008;6(9):1500-06.
24. Song X, Sander SD, Varker H, Amin A. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs.2012;12(4):245-53.
25. Patel AA, Reardon G, Nelson WW, Philpot T, Neidecker MV. Persistence of warfarin therapy for residents in long-term care who have atrial fibrillation. Clin Ther.2013;35(11):1794-804.
26. Raunsø J, Selmer C, Olesen JB, et al. Increased short-term risk of thrombo- embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J.2012;33(15):1886-92.
27. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med.2008;168(1):63-69.
28. Sherman DG, Kim SG, Boop BS, et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med.2005;165(10):1185-91.
29. Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm.2013;19(4):302-16. Available at:http://www.amcp.org/JMCP/2013/May/16520/1033.html.
30. Wang J, Liu X, Mullins CD. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. Curr Med Res Opin.2011;27(7):1303-13.
31. U.S. Food and Drug Administration. FDA drug safety communication:update on the risk for serious bleeding events with anticoagulant Pradaxa (dabigatran). August 14, 2014. Available at: http://www.fda.gov/drugs/drugsafety/ ucm326580.htm. Accessed May 15, 2015.
32. Truven Health Analytics. RED BOOK. Available at: http://www.redbook. com/redbook/. Accessed May 15, 2015.
33. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290(20):2685-92. Available at:http://jama.jamanetwork.com/article.aspx?articleid=197710. Accessed May 15, 2015.
34. Svendsen JH, Nielsen JC, Darkner S, et al. CHADS2 and CHA2DS2-VASc score to assess risk of stroke and death in patients paced for sick sinus syndrome. Heart. 2013;99(12):843-48. Available at: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC3664372/. Accessed May 15, 2015.
35. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal study: development and validation. J Chronic Dis. 1987;40(5):373-83.
36. Deitelzweig SB, Buysman E, Pinsky B, et al. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther.2013;35(8):1201-10.
37. Ruff CT, Giugliano RP, Branuwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383(9921):955-62.